Stedim enlists US partner to offer streamlined biomanufacturing
a Californian firm to bring to market an alternative to
conventional media kitchens, designed to reduce the costs of
biomanufacturing.
Biopharmaceutical companies are increasingly turning to disposable manufacturing to improve processing efficiency.
The AGT BioProcessing System, under development by Stedim and cell culture products firm Invitrogen, makes use of technology designed by Invitrogen's GIBCO BioProduction business.
The technology creates a granulated medium that produces specific ionic and pH conditions upon reconstitution in water. AGT media do not require additional supplementation or pH adjustment, saving valuable time and keeping media preparation areas cleaner and safer. In addition, the AGT granules dissolve much faster and produce less dust than traditional dry powder media.
Added to Stedim's sterile plastic bag technology, the combined system replaces conventional media kitchens with a means of hydrating the AGT media, sterile filtering and transfer into the bioreactor.
"The reduction in facilities validation, cleaning costs, transportation, warehousing and environmental control requirements make this combined ready to use system very cost effective in a time when optimal capacity management is critical for the biopharmaceutical industry," said Thierry Favreau, Stedim's CEO.
